News | Population Health | January 10, 2019

Mobile App Data Collection Shows Promise for Population Health Surveys

Researchers evaluate Medable Inc.’s mobile health survey solution as potential way to eliminate barriers to large-scale data collection

Mobile App Data Collection Shows Promise for Population Health Surveys

January 10, 2019 — Mobile app data collection can bring access to more potential clinical study participants, reduce clinical study timeframes and create more comprehensive sample sizes, according to research published in Survey Practice.

“It is critical that health and other national surveys represent the voice and experience of all Americans,” said senior author Ingrid Oakley-Girvan, senior vice president of research and strategy at Medable Inc., research director at the Public Health Institute, and associate member of the Canary Center at Stanford for Cancer Early Detection and the Stanford Cancer Institute. “Smartphone survey data can help policy makers allocate resources in realtime to respond to disease outbreaks such as opioid addiction. Our work sheds light on the value of smartphones to address declining participation rates, rising survey costs and poor coverage across demographics.”

Oakley-Girvan and co-authors Yasamin Miller, Cyrus DiCiccio, Juan Lavista, Cheryl Gore-Felton, Amanda Richardson, Carlos Acle, Jeff Hancock, Lorene Nelson and Oxana Palesh were interested in the impact that smartphones can have on health data survey collection.

They studied the response to a mobile app survey, built on the Medable Inc. platform, by deploying it in a college student population to determine if students would download the app, and to determine if the app would retain individuals in a study, two significant barriers being faced by researchers conducting population health surveys.  

“Our findings show that mobile app data collection can fundamentally change survey research,” said Miller, first author and founder and managing director of YMG. “Using mobile apps could create a shift in health surveys, which could eventually lead to faster and more accurate health policies and cures.”

Declining response rates to traditional telephone surveys are hindering researchers in their abilities to recruit and study the most pressing medical issues. The study used Medable Inc.’s platform to provide efficient real-world data collection, monitoring and analysis.

The researchers partnered with faculty from Stanford University, the Cancer Prevention Institute of California (CPIC), OneTree, YMG and Castleton University, to leverage Medable’s platform to collect behavioral health and substance use data. The researchers built and deployed two apps in under six weeks.

Medable’s end-to-end (E2E) platform enables researchers without developer expertise to create and deploy HIPAA-compliant iOS and Android apps for clinical trials or research studies. “Creating mobile applications on a short timeline would not have been possible without the use of Medable’s Axon,” said Miller. “Medable’s platform enabled team members without coding expertise to contribute and play key roles in developing the study.”

For more information: www.medable.com

Reference

Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now